DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Price, Quote, News and Overview
NASDAQ:DBVT - Nasdaq - US23306J2006 - ADR
DBVT Quote and Key Statistics
DBV TECHNOLOGIES SA-SPON ADR
NASDAQ:DBVT (1/21/2025, 8:00:00 PM)
Premarket: 4.52 0 (0%)4.52
+0.05 (+1.23%)
DBVT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.7% | ||
| ROE | -91.83% | ||
| Debt/Equity | 0.09 |
DBVT Performance and Technical Analysis
DBVT Ownership and Analysts
DBVT Latest News and Analysis
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies...
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Informations RéglementéesChâtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies...
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials.
Wall Street Poised To Open Lower A Day After Nasdaq's Record Close Above 20,000: Expert Flags 'Deterioration Under The Surface' As 117 S&P 500 Stocks Hit New Monthly Lows
U.S. stock futures declined on Thursday in premarket hours after hitting fresh highs on Wednesday. S&P 500, Dow, Nasdaq 100 & R2K were down.
About DBVT
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 106 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
DBV TECHNOLOGIES SA-SPON ADR
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES 92120 FR
CEO: Daniel Tasse
Employees: 106
Company Website: https://www.dbv-technologies.com/
Investor Relations: https://dbv-technologies.com/investor-overview/
Phone: 33155427878
DBVT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |